Loading...
A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol
INTRODUCTION: There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-β and has prevented cognitive decline in rodent mode...
Na minha lista:
| Udgivet i: | Alzheimers Dement (N Y) |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5651350/ https://ncbi.nlm.nih.gov/pubmed/29067312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.10.001 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|